Bristol Myers joins AstraZeneca, Merck in touting positive lung cancer drug use around surgery
Fierce Pharma
SEPTEMBER 22, 2023
In the perioperative treatment of early-stage non-small cell lung cancer with a PD-1/L1 inhibitor, Bristol Myers Squibb is touting a new trial win. The results follow positive readouts from AstraZeneca and Merck. . | It’s not a proper market showdown without all the players.
265 
Let's personalize your content